Background-We aimed to study sex-related differences in temporal trends in short-and long-term mortality from 1985 to 2008 in patients hospitalized for acute myocardial infarction. Methods and Results-We included a total of 14 434 consecutive patients admitted to our intensive coronary care unit between 1985 and 2008 for myocardial infarction. A total of 4028 patients (28%) were women. Women were more likely to present with a higher risk profile and were equally likely to receive pharmacological and invasive reperfusion therapy compared with men. Women had a higher unadjusted mortality rate at 30 days (odds ratio, 1.3; 95% confidence interval, 1.1-1.5) and during 20 years (hazard ratio, 1.1; 95% confidence interval, 1.0 -1.2) of follow-up. After adjustment for baseline characteristics, 30-day mortality was equal (adjusted odds ratio, 1.0; 95% confidence interval, 0.85-1.2) but the hazard for 20-year mortality was lower (adjusted hazard ratio, 0.77; 95% confidence interval, 0.66 -0.90) in women compared to men. For 30-day mortality, there was no significant interaction between sex and age, diagnosis, or diabetes mellitus. Survival improved between 1985 and 2008. Temporal mortality reductions between 1985 and 2008 were at least as high in women as in men with myocardial infarction for both 30-day mortality and long-term mortality hazard. Conclusions-The fact that adjusted mortality rates for men and women treated for myocardial infarction in an intensive coronary care unit were similar and declined markedly over a 24-year period suggests that both sexes benefit from the evidence-based therapies that have been developed and implemented during this time period. (Circulation. 2012;126: 2184-2189.)
C ardiovascular disease is the number 1 cause of death in women, and the total number of women who die of cardiovascular disease is higher than the number of men. 1 Myocardial infarction (MI) is the major cardiovascular cause of death in both sexes. Since 1985, considerable progress has been made in the management of MI and treatment outcomes; clinical evidence has guided the introduction of thrombolytic therapy, primary percutaneous coronary intervention (PCI), tailored treatment according to individual risk, and improved secondary prevention. [2] [3] [4] 
Clinical Perspective on p 2189
It has been suggested that women with MI may have benefitted less from the improvements in treatment and outcome that have occurred over the past 25 years because they were underrepresented in clinical trials. [5] [6] [7] [8] [9] However, no previous study has compared sex differences over a calendar period that included such marked changes in treatment and outcome of MI.
Furthermore, as a result of the progress made in the management of MI, at present, most patients hospitalized with MI survive until discharge. 4 For that reason, long-term outcomes after MI become increasingly important. However, only a limited number of studies have reported mortality rates after MI according to sex with a follow-up duration Ͼ1 year. 10 -12 Awareness of sex differences in patient characteristics, treatment, and outcome may eventually improve the clinical management and survival after MI in both women and men.
Therefore, the aims of the present study were to determine sex-related differences in baseline characteristics, treatment, short-term mortality, and long-term (20-year) mortality. Furthermore, we investigated whether the changes in mortality after MI that occurred between 1985 and 2008 were different for women and men. For this purpose, we analyzed 14 434 consecutive MI patients admitted to the intensive coronary care unit of the Erasmus Medical Center from 1985 to 2008.
Methods
We included all consecutive patients Ͼ18 years of age with a first admission for ST-segment-elevation MI (STEMI) or non-STEMI to the intensive coronary care unit of the Thoraxcenter at Erasmus University Medical Center between June 1985 and December 2008. 13 No other inclusion or exclusion criteria were used.
The diagnosis of MI was made in the presence of the following characteristics: chest pain or equivalent symptoms in combination with dynamic ECG changes consistent with MI and a typical serial rise (to at least 3 times the upper normal value) and fall in serum biochemical markers of cardiac necrosis such as creatine kinase-MB or troponin T. Patients were diagnosed as having STEMI in the presence of ST-segment elevation Ͼ0.1 mV in at least 2 contiguous peripheral leads or Ͼ0.2 mV in at least 2 contiguous precordial leads; they were diagnosed as having non-STEMI otherwise.
Trained physicians and nurses accustomed to the use of standardized case report forms collected the data. Demographic characteristics (age, sex), cardiac history (previous MI, PCI, or coronary artery bypass surgery), risk factors (hypertension, diabetes mellitus, hyperlipidemia, family history of coronary artery disease, smoking status), anemia (hemoglobin level Ͻ12.0 g/dL in women and Ͻ13.0 g/dL in men), renal dysfunction, and pharmacological and invasive treatment modalities (thrombolysis and PCI) were collected. Renal dysfunction was defined according to glomerular filtration rate estimated with the Modification of Diet in Renal Disease equation. 14 Hypertension, hyperlipidemia, and diabetes mellitus were defined as previously diagnosed by a physician or receiving medication to lower blood pressure, cholesterol, or glucose levels, respectively. Family history was defined as 1 or more relatives (parent or sibling) with MI diagnosed before 60 years of age.
The study end point was all-cause mortality at 30 days and during 20 years. Survival date was assessed through municipal civil registries, which are updated regularly and therefore highly accurate in the Netherlands. Follow-up was available for 98% of all patients.
This project was carried out in accordance with current rules of ethics and legislature. The ethics committee of the Erasmus Medical Center waived the need for its approval because register-based studies do not require ethical approval according to Dutch law.
Statistical Analysis
Categorical variables were summarized as percentages; continuous variables, as mean and standard deviation. The 2 test or Student t test was used to calculate P values as appropriate. To ease the display of descriptive results, sex ratios for each decade were computed to compare women and men. Cumulative survival curves according to sex were constructed with the Kaplan-Meier method and compared by the log-rank test.
We examined the independent association between sex and mortality or mortality hazard using logistic regression for 30-day outcome and the Cox proportional hazards model for long-term outcome, respectively. Adjustment was performed for the baseline variables age, previous MI, previous coronary artery bypass surgery, hypertension, diabetes mellitus, hyperlipidemia, family history of coronary artery disease, smoking status, renal dysfunction, anemia, diagnosis, and decade of hospital admission. Proportionality of hazards was tested graphically by inspection of log-log survival curves and by a formal test of proportionality based on Schoenfeld residuals. In the multivariable model, a multiple imputation algorithm with 5 imputations was used to handle the 2229 (15%) and 2347 (16%) patients in whom anemia status or renal function, respectively, was missing. Multiple imputation methods are known to be superior to complete case analyses. 15 In line with the literature, the association between sex and 30-day mortality was also examined in subgroups according to age (Ͻ65 and Ն65 years), diagnosis (STEMI or non-STEMI), and diabetes status. We assessed heterogeneity within these subgroups with a statistical test for interaction.
Similar multivariable models were used to assess changes in mortality from 1985 to 2008 in women and men separately. For this purpose, calendar periods of 3 years were compared. Results are reported as odds ratios for 30-day mortality and hazard ratios for long-term mortality and their respective 95% confidence intervals (CIs). All statistical tests were 2 tailed, and P values were considered significant at Ͻ0.05. To address multiplicity of testing for heterogeneity, P values for interaction were considered significant at Ͻ0.017 (0.05 divided by 3 because we defined subgroups according to 3 characteristics). 16 Analysis was performed with SPSS software version 20.0 (SPSS, Chicago, IL).
Results

Patient Characteristics
We included 14 434 patients, of whom 4028 (28%) were women. On average, women were 5 years older. In addition, compared with men, women more often had hypertension, diabetes mellitus, renal dysfunction, or anemia; less often were current smokers; and less often had a history of prior MI, PCI, coronary artery bypass surgery, or a diagnosis of STEMI (Table 1) . From 1985 to 2008, the patients became older on presentation ( Figure 1 ) and were more likely to have diabetes mellitus or anemia (P for trend Ͻ0.001 for all). Age at presentation increased uniformly in both women and men; therefore, the age difference between women and men remained Ϸ5 years during the study period. However, as a result of the changes in prevalence of risk factors over time, the cardiovascular risk profile at baseline in women became more comparable to that in men in the most recent period ( Table 1) .
Patient Management
Overall, sex disparities in initial and early medical management were limited ( Table 2) . Women with STEMI were equally likely to receive reperfusion therapy (by either thrombolytic therapy or PCI). With time, more patients received guideline-based therapy. No new sex disparities in the use of evidence-based management became apparent during the study period.
Sex and Mortality
A total of 106 517 person-years were analyzed. During the study period, 1544 women and 3708 men died. At 30 days, unadjusted mortality rates were higher in women than in men (7% versus 6%; odds ratio, 1.3; 95% CI, 1.1-1.5; Figure 2 ). However, after adjustment for age, the difference in 30-day mortality between women and men was no longer present (adjusted odds ratio, 1.0; 95% CI, 0.89 -1.2). After adjustment for all potential confounders, 30-day mortality remained the same (adjusted odds ratio, 1.0; 95% CI, 0.85-1.2; Table 3 ).
There was no heterogeneity in the association between sex and 30-day mortality in subgroups according to age (P for interactionϭ0.41), diagnosis (P for interactionϭ0.49), or diabetes mellitus (P for interactionϭ0.019; with significance at PϽ0.017 to address for multiplicity of testing).
At the 20-year follow-up, unadjusted mortality was slightly higher in women (71% versus 65%; hazard ratio, 1.1; 95% CI, 1.0 -1.2; Figure 2 ), but the adjusted 20-year mortality hazard was significantly lower in women compared with men (adjusted hazard ratio, 0.77; 95% CI, 0.66 -0.90; Table 3 ). 
Secular Trends in Mortality
Discussion
This study demonstrates that, during an observation period of 24 years, women hospitalized for an acute MI were more likely to present with a higher risk profile but were equally likely to receive pharmacological and invasive reperfusion therapy compared with men. The higher risk profile was mainly determined by an average age difference of 5 years between women and men. Women and men had the same adjusted mortality rates at 30 days, whereas during 20 years of follow-up, the mortality hazard was lower in women. Importantly, temporal improvements in 30-day mortality and long-term mortality hazard from 1985 to 2008 were substantial and at least as high in women as in men.
We showed that women were older and therefore presented with a higher risk profile compared with men, which is in line with previous studies. 11, [17] [18] [19] [20] [21] [22] In our multivariable analysis, these differences fully account for the higher unadjusted mortality in women compared with men. Therefore, it is unlikely that other differences between women and men, including differences in biological factors and in treatment, caused the higher unadjusted mortality rate in women.
Previous analyses have reported that in certain subgroups such as younger patients, the mortality risk may be a higher in women compared with men. 23, 24 Data from the US National Registry of Myocardial Infarction collected in the 1990s indicated an increased in-hospital mortality risk for young women compared with young men, with no mortality difference in the older population. 24 In our analysis, mortality appeared higher in young women compared with young men in the same calendar period (ie, the 1990s); however, this age-dependent sex gap completely disappeared in the next decade. Furthermore, no significant interaction was detected between sex and age when the patients of all 3 decades were pooled together. In this study, there was also no significant interaction between sex and diagnosis. Because most MI studies do not report significant interaction between sex and type of MI, 20, 25, 26 it is likely that our conclusions are robust for STEMI and non-STEMI patients.
We show borderline significant heterogeneity in the association between sex and 30-day mortality in subgroups according to baseline diabetes mellitus, such that among patients with diabetes mellitus, female sex might be associated with increased 30-day mortality. This finding is in part consistent with prior studies that noted an increased risk of adverse events after MI among women compared with men with diabetes mellitus. 27, 28 Clinical trials in the diabetic population might help to identify specific therapies to reduce their increased risk of death.
Our study is unique in that it shows long-term (20 year) mortality depending on sex. After admittance to the hospital, the adjusted hazard for long-term mortality is more favorable in women compared with men, similar to findings of their survival advantage in the general population. Although several studies have also shown that women are at a lower risk up to 12 months after the onset of MI, 18, 25 our adjusted analysis demonstrates for the first time that this assertion can be extended for up to 20 years in a contemporary population.
Contrary to previous studies that showed that mortality decreased less over time in women compared with men, 6 -8 we now show that the improvement in outcome after MI over the last 24 years is at least as substantial in women as it is in men. In this respect, it should be noted that the calendar period that we studied differed from those in previous studies. Our study was initiated in 1985, when thrombolysis became standard therapy, and extends to the present era, in which PCI became the standard therapy. 2 The conflicting observation between our study demonstrating that mortality improved over time at least as much in women as in men and previous studies that showed more improvement in men may be due to the relatively short time frame of these previous studies. 6 -8 In addition, in the present study, sex disparities in medical management were limited. This might have contributed to relatively favorable outcomes in women compared with studies in countries where women less often receive evidence-based management. 9 Thus, the present study might demonstrate a best-case scenario.
Strengths and Limitations
To the best of our knowledge, this is the first study investigating temporal trends in clinical characteristics, treatment, and outcome of patients with MI according to sex over a time period of 24 years with follow-up data up to 20 years. Although the present study has unique strengths, some limitations should be mentioned. First, given the nature of sex, this study reveals important associations but cannot prove causation. Second, this study is based on hospitalized patients only and did not account for possible sex differences in out-of-hospital deaths before admission. Finally, the present data are derived from a single center.
Conclusions
We showed that, among patients hospitalized for acute MI, women are more likely to present with a higher risk profile and were almost as likely as men to receive contemporary medical therapy. After adjustment for baseline differences, 30-day mortality was equal among women and men, whereas the adjusted 20-year mortality hazard was lower in women. Importantly, temporal improvements in short-and long-term mortality from 1985 to 2008 were substantial and similar for women and men. The temporal trends are encouraging and suggest that both men and women will benefit from further improvements in care for acute MI. 
CLINICAL PERSPECTIVE
During the past decades, medical management and outcomes of acute myocardial infarction have improved substantially. It has been suggested that women with myocardial infarction have benefitted less from these improvements in treatment and outcomes compared with men because they were underrepresented in clinical trials. With the present study, however, we are the first to test this suggestion over a 24-year study period. We demonstrate that adjusted short-and long-term mortality rates were similar and declined markedly and equally in women and men during the 24 years studied. Furthermore, we also present long-term mortality data, up to 20 years after the myocardial infarction, which are sparse. This study is important because it helps to direct both further research and further management, in which women deserve to be treated with the same evidence-based care. In addition, the observed temporal trends are encouraging and suggest that both men and women will benefit from further improvements in care for acute myocardial infarction.
